American Journal of Kidney Diseases
Volume 50, Issue 5 , Pages 865-879 , November 2007

Management of Glycemia in Patients With Diabetes Mellitus and CKD

  • Noah D. Lubowsky, MD
    • ,
  • Richard Siegel, MD
    • ,
  • Anastassios G. Pittas, MD, MS

      Affiliations

    • Corresponding Author InformationAddress correspondence to Anastassios G. Pittas, MD, MS, Division of Endocrinology, Diabetes and Metabolism, Tufts-New England Medical Center, 750 Washington St, #268, Boston, MA 02111.

Received 21 August 2007 ,Accepted 21 August 2007.

References 

  1. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(suppl 2):S12–S154
  2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–79
  3. US Renal Data System. USRDS 2003 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003;
  4. Muntner P, Coresh J, Powe NR, Klag MJ. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol. 2003;14:1568–1577
  5. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. [see comments] N Engl J Med. 1993;329:977–986
  6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  8. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117
  9. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  10. American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care. 2007;30(suppl 1):S4–S41
  11. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract. 2002;8:5–11
  12. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596–1605
  13. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int. 2001;59:702–709
  14. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes: Role of glycemic control. J Am Soc Nephrol. 2006;17(suppl 2):S86–S89
  15. Menon V, Greene T, Pereira AA, et al. Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease. J Am Soc Nephrol. 2005;16:3411–3417
  16. McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis. 2002;40:566–575
  17. Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care. 1998;21:116–120
  18. Feldt-Rasmussen B. Is there a need to optimize glycemic control in hemodialyzed diabetic patients?. Kidney Int. 2006;70:1392–1394
  19. Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: A 7-year observational study. Diabetes Care. 2006;29:1496–1500
  20. Morioka T, Emoto M, Tabata T, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001;24:909–913
  21. Wu MS, Yu CC, Yang CW, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant. 1997;12:2105–2110
  22. Williams ME, Lacson E, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int. 2006;70:1503–1509
  23. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30:1049–1055
  24. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100
  25. Rubenfeld S, Garber AJ. Abnormal carbohydrate metabolism in chronic renal failure (The potential role of accelerated glucose production, increased gluconeogenesis, and impaired glucose disposal). J Clin Invest. 1978;62:20–28
  26. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis. 2005;45:275–280
  27. Stumvoll M. Glucose production by the human kidney—Its importance has been underestimated. Nephrol Dial Transplant. 1998;13:2996–2999
  28. Rave K, Heise T, Pfutzner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24:886–890
  29. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients. Diabet Med. 2003;20:642–645
  30. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes. 2002;51:1226–1232
  31. Bannon P, Lessard F, Lepage R, Joly JG, Dufresne L. Glycated hemoglobin in uremic patients as measured by affinity and ion-exchange chromatography. Clin Chem. 1984;30:485–486
  32. Little RR, Tennill AL, Rohlfing C, et al. Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure?. Clin Chem. 2002;48:784–786
  33. Nakao T, Matsumoto H, Okada T, et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med (Tokyo, Japan). 1998;37:826–830
  34. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the look AHEAD trial. Diabetes Care. 2007;30:1374–1383
  35. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443
  36. Stenman S, Melander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose?. Ann Intern Med. 1993;118:169–172
  37. Brier ME, Bays H, Sloan R, Stalker DJ, Welshman I, Aronoff GR. Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. Am J Kidney Dis. 1997;29:907–911
  38. Jonsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol. 1998;53:429–435
  39. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care. 1994;17:1026–1030
  40. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis. 2000;35:500–505
  41. Aventis: Prescribing information for Amaryl. Aventis, Bridgewater, NJ, 2007
  42. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39:1617–1624
  43. Asplund K, Wiholm BE, Lundman B. Severe hypoglycaemia during treatment with glipizide. Diabet Med. 1991;8:726–731
  44. Holstein A, Plaschke A, Hammer C, Egberts EH. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol. 2003;59:91–97
  45. Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J. Pharmacokinetics of glipizide in man: Influence of renal insufficiency. Diabetologia. 1973;9:331–338
  46. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17:365–370
  47. Prescribing information for Prandin. Princeton, NJ: Novo Nordisk; 2007;
  48. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003;26:886–891
  49. Prescribing information for Starlix. East Hanover, NJ: Novartis; 2007;
  50. Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract. 2003;59:191–194
  51. Inoue T, Shibahara N, Miyagawa K, et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol. 2003;60:90–95
  52. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705
  53. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007;298:194–206
  54. Lilly: Prescribing information for Byetta. Amylin Pharmaceuticals, San Diego, CA, 2007
  55. Merck: Prescribing information for Januvia. Merck, Whitehouse Station, NJ, 2007
  56. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30:1862–1864
  57. Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther. 2005;27:1500–1512
  58. Prescribing information for Symlin. San Diego, CA: Amylin Pharmaceuticals; 2007;
  59. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Ann Intern Med. 2002;137:25–33
  60. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963–1972
  61. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews (Online). 2006;CD002967
  62. Lilly: Prescribing information for Actos. Pharmaceuticals America, Inc, Lincolnshire, IL, 2007
  63. Glaxo Smith Kline: Prescribing information for Avandia. Glaxo Smith Kline, Research Triangle Park, NC, 2007
  64. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompor T, Eckland D. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol. 2003;55:368–374
  65. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471
  66. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes—An interim analysis. N Engl J Med. 2007;357:28–38
  67. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet. 2002;359:2072–2077
  68. Bayer Corp: Prescribing information for Precose. West Haven, CT, Bayer Corp, 2007
  69. Pharmacia: Prescribing information for Glyset. Kalamazoo, MI, Pharmacia, 2007
  70. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) Study. Diabetes Care. 2005;28:2673–2679
  71. Mooradian AD, Bernbaum M, Albert SG. Narrative review: A rational approach to starting insulin therapy. Ann Intern Med. 2006;145:125–134
  72. Ceglia L, Lau J, Pittas AG. Meta-analysis: Efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med. 2006;145:665–675
  73. Pfizer: Prescribing information for Exubera. Pfizer, New York, NY, 2007
  74. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care. 2002;25:583–592
  75. Markell M. New-onset diabetes mellitus in transplant patients: Pathogenesis, complications, and management. Am J Kidney Dis. 2004;43:953–965
  76. Hur KY, Kim MS, Kim YS, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care. 2007;30:609–615
  77. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an International Expert Panel Meeting. Barcelona, Spain, 19 February 2003 Transplantation. 2003;75(suppl):S3–S24
  78. Hricik DE, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation. 1991;51:374–377
  79. Turk T, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant. 2006;6:842–846
  80. Pietruck F, Kribben A, Van TN, et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int. 2005;18:483–486
  81. Luther P, Baldwin D. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant. 2004;4:2135–2138
  82. Nevalainen PI, Lahtela JT, Mustonen J, Pasternack A. Subcutaneous and intraperitoneal insulin therapy in diabetic patients on CAPD. Perit Dial Int. 1996;16(suppl 1):S288–S291
  83. Johnson C, Simmons WD. Dialysis of Drugs. USA: Nephrology Pharmacy Associates, Inc; 2006;
  84. Quellhorst E. Insulin therapy during peritoneal dialysis: Pros and cons of various forms of administration. J Am Soc Nephrol. 2002;13(suppl 1):S92–S96
  85. Manske CL. Hyperglycemia and intensive glycemic control in diabetic patients with chronic renal disease. Am J Kidney Dis. 1998;32(suppl 3):S157–S171
  86. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis. 2005;46:713–719

 Originally published online as doi:10.1053/j.ajkd.2007.08.012 on October 4, 2007.

PII: S0272-6386(07)01149-3

doi: 10.1053/j.ajkd.2007.08.012

American Journal of Kidney Diseases
Volume 50, Issue 5 , Pages 865-879 , November 2007

Article Tools